BRNS Research | Milton Maxwell

BRNS

Barinthus Biotherapeutics plc

0.7385

-0.0015-0.2%

Dec 16, 4:00:01 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

30.15M

P/E (TTM)

Basic EPS (TTM)

-1.88

Dividend Yield

Recent Filings

8-K

PAO steps down April 30

3/31/26Mar 31, 2026

Barinthus Biotherapeutics' principal accounting officer Gemma Jones, an employee of CFGI, will step down effective April 30, 2026, after notifying the company on March 27. No successor named yet. Leadership transition adds uncertainty amid pipeline risks and funding challenges.

10-K

FY2025 results

3/13/26Mar 13, 2026

Barinthus Biotherapeutics reported FY2025 net loss of $66.5M, up from $61.2M in FY2024, amid pipeline refocus slashing workforce 65% in January 2025 and deprioritizing legacy infectious disease and oncology assets. Q4 saw Phase 1 AVALON celiac trial update: VTP-1000 well-tolerated across doses in 18 patients, dose-dependent pharmacology. R&D expenses dropped 39% y/y to $25.6M as viral vector trials wrapped; cash burn accelerated to $48M from $29M amid forex losses. Cash fell to $71.9M, runway into 2027. Merger with Clywedog eyed for Q2 2026 closure. Nasdaq bid price below $1 signals delisting risk.

8-K

Merger and 2025 results out

3/13/26Mar 13, 2026

Barinthus Bio reported 2025 results with cash at $71.9M, down from $112.4M after $48M pipeline burn, yet runway covers 12 months standalone. All-stock merger with Clywedog advances, set for Q2 2026 close under new name Clywedog Therapeutics Holdings (CLYD) with cash through 2027. VTP-1000 Phase 1 celiac data looms H2 2026. Merger risks closing delays.

8-K

Merger amendment adjusts ratios

2/23/26Feb 23, 2026

Barinthus amended its merger agreement with Clywedog on February 22, 2026, tweaking exchange ratios—Scheme now 0.1-0.166667, Merger 0.000305-0.000508—to preserve ownership split amid U.S. shutdown delays. Minimum cash thresholds expanded for assumed closings May 31 and June 30, 2026. Deal faces court and shareholder approvals. Timeline slipped.

8-K

Nasdaq bid price noncompliance notice

1/6/26Jan 6, 2026

Barinthus Biotherapeutics received a Nasdaq notice on December 30, 2025, for ADS bid price below $1.00 over 30 business days, violating Listing Rule 5450(a)(1). ADSs stay listed under BRNS with 180 days to June 29, 2026, to hit $1.00 for 10 straight days. No immediate delisting. Company eyes reverse stock split.

About

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targeting chronic hepatitis B virus infection; VTP-200, a potential non-invasive treatment for persistent high-risk human papillomavirus; VTP-850, an immunotherapeutic candidate for prostate cancer; VTP-600, an immunotherapeutic candidate targeting MAGE-A3 and NY-ESO1 antigens; VTP-500, a prophylactic vaccine candidate to prevent middle east respiratory syndrome; VTP-400, a prophylactic vaccine candidate for shingles; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

CEO

Mr. William J. Enright MBA

IPO

4/30/2021

Website

https://www.barinthusbio.com

Employees

105

Sector

Healthcare

Industry

Biotechnology